Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Psychopharmacology
Yu-Fang ChengHan-Ting Zhang

Abstract

Cyclic AMP signaling plays an important role in memory loss associated with Alzheimer's disease (AD). However, little is known about whether inhibition of phosphodiesterase-4 (PDE4), which increases intracellular cAMP, reverses β-amyloid peptide (Aβ)-induced memory deficits. Experiments were performed to demonstrate the effect of the PDE4 inhibitor rolipram on memory impairment produced by Aβ1-40 (Aβ40) or its core fragment Aβ25-35. We tested memory using Morris water-maze and passive avoidance tasks and examined expression of phosphorylated cAMP response-element binding protein (pCREB) in the hippocampus in rats treated with Aβ25-35 or Aβ40 into bilateral CA1 subregions, with or without rolipram administration. Aβ25-35 (10 μg/side) increased escape latency during acquisition training and decreased swimming time and distance in the target quadrant in the water-maze probe trial; it also decreased 24-h retention in the passive avoidance paradigm. All these were reversed by chronic administration of rolipram (0.5 mg/kg). Similarly, Aβ40 (4 μg/side) produced memory impairment, as demonstrated by decreased retention in passive avoidance; this was also reversed by repeated treatment with rolipram. In addition, rolipram blocked extinc...Continue Reading

References

Jun 5, 1995·Brain Research·J ClearyE O'Hare
May 13, 1996·Brain Research·S Y ChenC D Barnes
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·C H BaileyE R Kandel
Jan 14, 1997·European Journal of Pharmacology·S DelobetteT Maurice
Jul 1, 1997·Neurobiology of Learning and Memory·W A SweeneyJ B Overmier
May 26, 1998·Acta Neuropathologica·J J Miguel-Hidalgo, R Cacabelos
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M P LambertW L Klein
Jul 21, 1998·European Journal of Pharmacology·K YamadaT Nabeshima
Nov 3, 1998·Lancet·C F LippaP St George-Hyslop
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M BaradE Kandel
Sep 4, 1999·Behavioural Brain Research·J H MedinaI Izquierdo
Sep 24, 1999·Pharmacology, Biochemistry, and Behavior·J S SilvestreJ M Palacios
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·S Sinha, I Lieberburg
Mar 21, 2000·Journal of Neuroscience Research·Q S ChenC W Xie
Jul 7, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H T ZhangJ M O'Donnell
Feb 28, 2001·European Journal of Pharmacology·H H WangC F Chen
Mar 29, 2001·Physiological Reviews·D J Selkoe
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·M R ViannaI Izquierdo
Apr 27, 2002·Journal of Neurophysiology·Miao-Kun Sun, Daniel L Alkon
Sep 24, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ottavio V VitoloMichael Shelanski
Oct 16, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Han-Ting ZhangJames M O'Donnell
Aug 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rusiko BourtchouladzeTim Tully
Apr 29, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Han-Ting ZhangJames M O'Donnell
Jul 30, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Liqi TongCarl W Cotman
Aug 11, 2004·Behavioural Brain Research·Mauro GiorgiAntonella Gasbarri

❮ Previous
Next ❯

Citations

Jul 31, 2013·Neuropharmacology·R AnandAbbas Ali Mahdi
Nov 23, 2012·ACS Chemical Neuroscience·Ana García-OstaRafael Franco
Aug 13, 2011·Human Molecular Genetics·Albert GiraltEsther Pérez-Navarro
Apr 2, 2014·Nature Reviews. Drug Discovery·Donald H MauriceVincent C Manganiello
Jul 26, 2013·Expert Opinion on Therapeutic Targets·Wito RichterMarco Conti
Jul 22, 2011·Expert Opinion on Pharmacotherapy·Robert A KlonerVera J Stecher
Jul 30, 2011·Journal of Ethnopharmacology·Yuan LiuPengtao Li
Jun 24, 2011·BioFactors·Ana M M Oliveira, Hilmar Bading
Dec 7, 2013·Molecular Nutrition & Food Research·Jan Kevin Schluesener, Hermann Schluesener
Jul 19, 2011·Brain Research·Tanja S SteiningerHubert H Kerschbaum
Jan 28, 2014·Biochemical Pharmacology·Daniela PuzzoOttavio Arancio
Feb 9, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Thieza G MeloRegina H Silva
Mar 29, 2016·Neural Plasticity·Sung-Soo Jang, Hee Jung Chung
May 17, 2014·The International Journal of Neuropsychopharmacology·Miaojun LaiWenhua Zhou
Jul 8, 2011·The International Journal of Neuropsychopharmacology·Chuang WangHan-Ting Zhang
Feb 26, 2015·Pharmacological Reports : PR·Anil Kumar Ekavali
Jan 13, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew F TeichOttavio Arancio
Nov 6, 2014·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark E GurneyAlex B Burgin
Dec 3, 2014·Neurobiology of Aging·Fuyuki Kametani, Seiichi Haga
May 24, 2012·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Crystal L LantzAlexandre E Medina
Sep 22, 2015·Chemistry & Biology·Pia R LundegaardE Elizabeth Patton
Oct 24, 2019·Biochemical Society Transactions·Amy J TibboGeorge S Baillie
Jun 9, 2011·British Journal of Pharmacology·O BrunoR Ricciarelli
Sep 7, 2019·The Journal of Pharmacology and Experimental Therapeutics·Su-Ying CuiJames M O'Donnell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.